Apellis Pharmaceuticals - APLS Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $78.40
Forecasted Upside: 26.35%
Number of Analysts: 14
Breakdown:
1 Sell Ratings
4 Hold Ratings
8 Buy Ratings
1 Strong Buy Ratings

^$62.05 As of 03/24/2023 01:21 PM ET

▼ -1.17 (-1.85%)

1 month | 3 months | 12 months

Get New Apellis Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for APLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLS

^$78.40

▲ +26.35% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $78.40, with a high forecast of $139.00 and a low forecast of $40.00. The average price target represents a 26.35% upside from the last price of $62.05.

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Apellis Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
9 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

9/29/2021

1 strong buy ratings
9 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

12/28/2021

1 strong buy ratings
9 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

3/28/2022

1 strong buy ratings
9 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

6/26/2022

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

9/24/2022

1 strong buy ratings
8 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

12/23/2022

1 strong buy ratings
8 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

2/21/2023

1 strong buy ratings
8 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

3/23/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/9/2023	Citigroup	Lower Target		$91.00 ➝ $88.00	Low
2/22/2023	Raymond James	Boost Target	Strong-Buy	$123.00 ➝ $139.00	N/A
2/21/2023	Bank of America	Boost Target		$79.00 ➝ $115.00	Low
2/21/2023	Stifel Nicolaus	Boost Target	Buy	$65.00 ➝ $75.00	Low
2/21/2023	Robert W. Baird	Boost Target	Outperform	$90.00 ➝ $105.00	Low
2/21/2023	HC Wainwright	Boost Target	Buy	$75.00 ➝ $87.00	Low
2/21/2023	Citigroup	Boost Target	Buy	$86.00 ➝ $91.00	Low
2/21/2023	Needham & Company LLC	Boost Target	Buy	$70.00 ➝ $80.00	Low
1/2/2023	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$83.00 ➝ $58.00	Low
11/15/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$81.00 ➝ $79.00	Low
11/10/2022	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$70.00 ➝ $40.00	Low
11/8/2022	Credit Suisse Group	Lower Target	Neutral	$45.00 ➝ $43.00	Low
11/8/2022	Wedbush	Lower Target		$59.00 ➝ $47.00	Low
10/18/2022	Raymond James	Boost Target	Strong-Buy	$113.00 ➝ $123.00	Low
9/12/2022	Wedbush	Boost Target	Neutral	$55.00 ➝ $67.00	Low
9/8/2022	Stifel Nicolaus	Boost Target	Buy	$60.00 ➝ $65.00	Low
8/18/2022	Oppenheimer	Boost Target	Outperform	$68.00 ➝ $78.00	Low
8/9/2022	Credit Suisse Group	Boost Target	Neutral	$49.00 ➝ $52.00	Low
8/9/2022	Raymond James	Boost Target	Strong-Buy	$102.00 ➝ $113.00	Low
8/9/2022	The Goldman Sachs Group	Boost Target	Buy	$91.00 ➝ $102.00	Low
7/20/2022	Citigroup	Boost Target	Buy	$81.00 ➝ $86.00	Low
7/19/2022	HC Wainwright	Initiated Coverage	Buy	$75.00	Low
6/16/2022	Stifel Nicolaus	Initiated Coverage	Buy		High
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$94.00 ➝ $84.00	Medium
5/20/2022	Credit Suisse Group	Boost Target		$49.00	High
5/5/2022	Raymond James	Lower Target		$114.00 ➝ $102.00	High
4/13/2022	Roth Capital	Downgrade	Neutral ➝ Sell	$40.00	Low
4/4/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$66.00 ➝ $69.00	High
3/17/2022	Citigroup	Reiterated Rating	Focus List	$81.00	High
3/16/2022	Robert W. Baird	Boost Target	Outperform ➝ Outperform	$83.00 ➝ $90.00	Medium
3/7/2022	The Goldman Sachs Group	Lower Target	Buy	$102.00 ➝ $86.00	High
3/1/2022	Raymond James	Boost Target	Strong-Buy	$112.00 ➝ $114.00	High
1/11/2022	Raymond James	Lower Target	Strong-Buy	$116.00 ➝ $112.00	High
1/7/2022	The Goldman Sachs Group	Boost Target		$100.00 ➝ $102.00	Low
12/31/2021	Needham & Company LLC	Reiterated Rating	Buy	$70.00	N/A
12/8/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$84.00	Medium
11/29/2021	Roth Capital	Reiterated Rating	Buy ➝ Neutral	$46.00 ➝ $40.00	Medium
11/24/2021	Citigroup	Boost Target	Buy	$65.00 ➝ $72.00	Medium
11/9/2021	Wedbush	Lower Target	Neutral ➝ Neutral	$34.00 ➝ $28.00	High
11/9/2021	Raymond James	Boost Target	Strong-Buy	$102.00 ➝ $116.00	High
9/13/2021	Robert W. Baird	Boost Target	Outperform	$75.00 ➝ $80.00	High
9/12/2021	Raymond James	Upgrade	Outperform ➝ Strong-Buy		High
9/10/2021	Robert W. Baird	Reiterated Rating	Buy	$75.00	High
9/10/2021	BMO Capital Markets	Lower Target	Outperform	$89.00 ➝ $69.00	High
9/10/2021	Needham & Company LLC	Lower Target	Buy	$85.00 ➝ $70.00	High
9/10/2021	Roth Capital	Lower Target	Buy	$80.00 ➝ $46.00	High
9/10/2021	Oppenheimer	Lower Target	Outperform	$80.00 ➝ $65.00	High
9/10/2021	Credit Suisse Group	Lower Target	Neutral	$50.00 ➝ $38.00	High
9/10/2021	Wedbush	Downgrade	Outperform ➝ Neutral	$71.00 ➝ $39.00	High
8/19/2021	Wedbush	Upgrade	Neutral ➝ Outperform		High
8/19/2021	Jefferies Financial Group	Initiated Coverage	Buy	$74.00	High
8/10/2021	Needham & Company LLC	Reiterated Rating	Buy	$85.00	Medium
8/10/2021	Credit Suisse Group	Boost Target	Neutral	$44.00 ➝ $50.00	High
8/10/2021	Raymond James	Lower Target	Strong-Buy	$115.00 ➝ $102.00	High
7/19/2021	Needham & Company LLC	Initiated Coverage	Buy	$85.00	Medium
7/12/2021	Needham & Company LLC	Reiterated Rating	Buy	$85.00	Medium
7/8/2021	BMO Capital Markets	Boost Target	Outperform	$68.00 ➝ $89.00	High
7/2/2021	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$91.00 ➝ $101.00	Low
7/1/2021	Cowen	Boost Target	Outperform	$60.00 ➝ $70.00	High
6/28/2021	Needham & Company LLC	Boost Target	Buy	$65.00 ➝ $85.00	Medium
5/20/2021	UBS Group	Initiated Coverage	Buy	$82.00	Low
5/18/2021	BMO Capital Markets	Boost Target	Outperform	$64.00 ➝ $68.00	High
5/18/2021	Oppenheimer	Boost Target	Outperform ➝ Outperform	$64.00 ➝ $67.00	Medium
5/17/2021	Raymond James	Boost Target	Strong-Buy	$104.00 ➝ $115.00	Medium
5/17/2021	Roth Capital	Boost Target	Buy	$69.00 ➝ $80.00	High
4/29/2021	Credit Suisse Group	Boost Target	Neutral	$37.00 ➝ $39.00	High
4/16/2021	The Goldman Sachs Group	Initiated Coverage	Buy	$130.00	Medium
2/26/2021	Credit Suisse Group	Boost Target	Neutral	$35.00 ➝ $37.00	High
1/29/2021	Credit Suisse Group	Boost Target	Neutral	$31.00 ➝ $35.00	High
1/8/2021	Raymond James	Boost Target	Strong-Buy	$78.00 ➝ $104.00	Low
12/15/2020	Roth Capital	Boost Target	Buy	$50.00 ➝ $73.00	Low
12/10/2020	Cowen	Boost Target	Outperform	$45.00 ➝ $55.00	Medium
12/4/2020	JPMorgan Chase & Co.	Boost Target		$50.00 ➝ $875.00	Medium
12/1/2020	BMO Capital Markets	Boost Target	Outperform	$57.00 ➝ $66.00	Low
11/23/2020	Smith Barney Citigroup	Boost Target		$53.00 ➝ $67.00	Low
11/19/2020	Needham & Company LLC	Initiated Coverage	Buy	$59.00	Low
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
8/31/2020	Stifel Nicolaus	Initiated Coverage	Buy	$40.00	High
7/20/2020	Roth Capital	Initiated Coverage	Buy	$50.00	High
6/30/2020	Citigroup	Lower Target	Buy	$56.00 ➝ $54.00	High
6/16/2020	BTIG Research	Initiated Coverage	Neutral		High
6/12/2020	Oppenheimer	Reiterated Rating	Buy	$62.00	High
6/8/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$54.00 ➝ $56.00	High
5/28/2020	UBS Group	Initiated Coverage	Add		Medium
4/28/2020	Cantor Fitzgerald	Boost Target	Overweight	$54.00 ➝ $61.00	High
3/31/2020	Raymond James	Initiated Coverage	Strong-Buy	$86.00	High
3/31/2020	BMO Capital Markets	Initiated Coverage	Outperform	$54.00	High
3/11/2020	Wedbush	Upgrade	Underperform ➝ Neutral	$29.00	High
3/2/2020	Credit Suisse Group	Lower Target	Neutral	$36.00 ➝ $34.00	High
2/28/2020	Cowen	Reiterated Rating	Buy	$40.00	High
1/7/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$54.00	High
1/7/2020	Oppenheimer	Boost Target	Buy	$52.00 ➝ $62.00	High
1/7/2020	Citigroup	Boost Target		$37.00 ➝ $80.00	High
1/7/2020	Cowen	Reiterated Rating	Buy	$40.00	High
1/7/2020	SVB Leerink	Initiated Coverage	Market Perform	$30.00	High
1/7/2020	Robert W. Baird	Reiterated Rating	Outperform ➝ Overweight	$45.00 ➝ $70.00	High
12/19/2019	Bank of America	Initiated Coverage	Buy	$36.00	High
11/27/2019	Wedbush	Initiated Coverage	Underperform	$23.00	N/A
11/25/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$50.00 ➝ $54.00	Medium
11/21/2019	Wedbush	Initiated Coverage	Underperform	$23.00	High
11/5/2019	Credit Suisse Group	Initiated Coverage	Neutral	$33.00	Medium
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
8/1/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$52.00 ➝ $50.00	Low
7/31/2019	Cowen	Set Target	Buy	$40.00	Medium
7/12/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$35.00 ➝ $49.00	High
7/9/2019	Oppenheimer	Initiated Coverage	Outperform	$52.00 ➝ $52.00	High
6/16/2019	Cowen	Reiterated Rating	Buy	$40.00	High
5/8/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$52.00	Medium
3/28/2019	Robert W. Baird	Initiated Coverage	Outperform ➝ Outperform	$45.00	Low
2/28/2019	Cantor Fitzgerald	Set Target	Buy	$57.00	High
1/23/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$34.00	High
1/8/2019	B. Riley	Initiated Coverage	Buy	$40.00	Low
12/20/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$53.00	High
12/6/2018	Citigroup	Boost Target	Buy	$34.00 ➝ $40.00	Medium
12/3/2018	Cantor Fitzgerald	Set Target	Buy	$53.00	High
11/14/2018	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$38.00 ➝ $34.00	High
11/12/2018	Cantor Fitzgerald	Set Target	Buy	$53.00	Low
10/1/2018	Cantor Fitzgerald	Set Target	Buy	$53.00	Low
9/13/2018	B. Riley	Boost Target	Buy	$27.00 ➝ $40.00	Low
9/4/2018	Cantor Fitzgerald	Set Target	Buy	$53.00	High
8/7/2018	Cantor Fitzgerald	Boost Target	Overweight ➝ Buy	$52.00 ➝ $53.00	Medium
8/1/2018	Cowen	Reiterated Rating	Buy	$40.00	Medium
7/31/2018	Cantor Fitzgerald	Set Target	Buy	$52.00	High
7/30/2018	B. Riley	Upgrade	Neutral ➝ Buy	$27.00	High
7/10/2018	Cowen	Initiated Coverage	Outperform	$40.00	Low
6/27/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$52.00	High
6/7/2018	Cantor Fitzgerald	Set Target	Buy	$52.00	Low
5/23/2018	Cantor Fitzgerald	Initiated Coverage	Overweight		Low
4/12/2018	B. Riley	Downgrade	Buy ➝ Neutral	$27.00	High

(Data available from 3/24/2018 forward)

News Sentiment Rating

1.13 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
6 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

8/26/2022

3 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/25/2022

5 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

10/25/2022

6 very positive mentions
5 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

11/24/2022

2 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/24/2022

5 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/23/2023

13 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/22/2023

17 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/24/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

msn.com
3/15/2023
Apellis Pharmaceuticals' Empaveli sNDA action date extended by FDA
americanbankingnews.com
3/15/2023
Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Price Target at $78.40
marketbeat.com
3/12/2023
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Moderate Buy" by Brokerages
finance.yahoo.com
2/27/2023
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
marketbeat.com
2/27/2023
Jefferies Financial Group Comments on Apellis Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:APLS)

Very Positive

americanbankingnews.com
3/23/2023
Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock
marketbeat.com
3/22/2023
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Harbour Capital Advisors LLC
marketbeat.com
3/21/2023
Assenagon Asset Management S.A. Trims Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
marketbeat.com
3/18/2023
Teachers Retirement System of The State of Kentucky Purchases New Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
marketbeat.com
3/17/2023
Parallax Volatility Advisers L.P. Sells 106,610 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Today's Range

Now: $62.05

$61.78

$63.19

50 Day Range

MA: $58.00

$50.49

$66.96

52 Week Range

Now: $62.05

$33.32

$70.75

Volume

469,732 shs

Average Volume

1,694,289 shs

Market Capitalization

$6.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Apellis Pharmaceuticals?: The following Wall Street research analysts have issued research reports on Apellis Pharmaceuticals in the last year: Bank of America Co., Citigroup Inc., Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Roth Capital, Stifel Nicolaus, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for APLS.
What is the current price target for Apellis Pharmaceuticals?: 15 Wall Street analysts have set twelve-month price targets for Apellis Pharmaceuticals in the last year. Their average twelve-month price target is $78.40, suggesting a possible upside of 26.3%. Raymond James has the highest price target set, predicting APLS will reach $139.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $40.00 for Apellis Pharmaceuticals in the next year.
View the latest price targets for APLS.
What is the current consensus analyst rating for Apellis Pharmaceuticals?: Apellis Pharmaceuticals currently has 1 sell rating, 4 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLS will outperform the market and that investors should add to their positions of Apellis Pharmaceuticals.
View the latest ratings for APLS.
What other companies compete with Apellis Pharmaceuticals?: Other companies that are similar to Apellis Pharmaceuticals include Legend Biotech, Ascendis Pharma A/S, Karuna Therapeutics, Organon & Co. and Roivant Sciences. Learn More about companies similar to Apellis Pharmaceuticals.
How do I contact Apellis Pharmaceuticals' investor relations team?: Apellis Pharmaceuticals' physical mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company's listed phone number is (617) 977-5700 and its investor relations email address is [email protected] The official website for Apellis Pharmaceuticals is www.apellis.com. Learn More about contacing Apellis Pharmaceuticals investor relations.

Apellis Pharmaceuticals - APLS Stock Price Target and Predictions

Analyst Price Target for APLS

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.13 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Apellis Pharmaceuticals?

What is the current price target for Apellis Pharmaceuticals?

What is the current consensus analyst rating for Apellis Pharmaceuticals?

What other companies compete with Apellis Pharmaceuticals?

How do I contact Apellis Pharmaceuticals' investor relations team?